1387PRandomized, double-blind, placebo (P)-controlled phase III non-inferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: An ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) ≤10.0 g/dL. (23rd October 2018) - Henry, D; Hirsh, V; Kubota, K; Steinmetz, T; Thomas, G; Kang, J-H; Gordon, D; Orlov, S; Fleishman, A N; De Oliveira Brandao, C